share_log

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics将参加即将举行的投资者会议
Macrogenics ·  05/13 00:00
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics将参加即将举行的投资者会议

ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:

马里兰州罗克维尔,2024年5月13日(GLOBE NEWSWIRE)——专注于开发、制造和商业化用于治疗癌症的创新单克隆抗体疗法的生物制药公司MacroGenics, Inc.(纳斯达克股票代码:MGNX)今天宣布,该公司的管理层将参加本月的以下投资者会议:

    • The Citizens JMP Life Sciences Conference (New York). MacroGenics' President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Tuesday, May 14, 2024, at 10:30 am ET. MacroGenics' management will also participate in one-on-one meetings.
    • TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA (Virtual). MacroGenics' President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, May 29, 2024, at 12:30 pm ET.
    • Citizens JMP 生命科学会议(纽约)。MacroGenics总裁兼首席执行官斯科特·科尼格医学博士、博士将于美国东部时间2024年5月14日星期二上午10点30分参加炉边谈话。Macrogenics的管理层还将参加一对一的会议。
    • TD Cowen的第五届年度肿瘤学创新峰会:ASCO和EHA见解(虚拟)。MacroGenics总裁兼首席执行官斯科特·科尼格医学博士、博士将于美国东部时间2024年5月29日星期三中午12点30分参加炉边谈话。

Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days.

可以在Macrogenics网站投资者关系部分的 “活动与演讲” 下访问上述演讲的网络直播 http://ir.macrogenics.com/events.cfm。公司将在其网站上保留这些网络广播的存档重播30天。

About MacroGenics, Inc.

关于 MacroGenics, Inc.

MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

MacroGenics(以下简称 “公司”)是一家生物制药公司,专注于开发、制造和商业化用于治疗癌症的基于单克隆抗体的创新疗法。该公司主要从其专有的下一代抗体技术平台套件中生成候选产品线,这些平台适用于广泛的治疗领域。MacroGenics的技术平台和蛋白质工程专业知识相结合,使公司能够开发出有前途的候选产品,并与全球制药和生物技术公司进行多项战略合作。欲了解更多信息,请访问公司的网站 wwwmacrogenics.com。MacroGenics 和 MacroGenics 徽标是 MacroGenics, Inc. 的商标或注册商标。

###

###

CONTACT: Jim Karrels, Senior Vice President, CFO 1-301-251-5172,  info@macrogenics.com
联系人:吉姆·卡雷尔斯,高级副总裁,首席财务官 1-301-251-5172,  info@macrogenics.com

Primary Logo

Source: MacroGenics, Inc.

资料来源:MacroGenics, Inc.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发